You are here

Generic Betapace Receives Final Approval

PITTSBURGH, Feb. 8 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE:MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sotalol Hydrochloride Tablets USP (AF), 80mg, 120mg and 160mg.

Sotalol Hydrochloride Tablets USP (AF) are the generic version of Berlex Inc.'s Betapace AF(TM) Tablets, which had U.S. sales of approximately $10.5 million for the same strengths in the 12-month period ending Dec. 31, 2006, according to IMS Health.

This product will be shipped immediately.

Source: Mylan

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs